Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases

Radiotherapy and Oncology

Volumn 80, Issue 2, 2006, Pages 185-191

  Raju, Uma ^a   Ariga, Hisanori ^a   Koto, Masashi ^a   Lu, Xueguan ^a   Pickett, Jessica ^a   Valdecanas, David ^a   Mason, Kathryn A ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cdks; Flavopiridol; Radiosensitization; SEG 1; Tumor xenografts

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; FLAVOPIRIDOL; RNA POLYMERASE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; GAMMA RADIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; WESTERN BLOTTING; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FLAVONOIDS; HUMANS; MICE; MICE, NUDE; PIPERIDINES; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748048523     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.07.027     Document Type: Article

References (32)

1. Arguello F., Alexander M., Sterry J.A., et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppressant, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91 (1998) 2482-2490
2. Bani-Hani K., Martin I.G., Hardie L.J., et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92 (2000) 1316-1321
3. Bible K.C., and Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57 (1997) 3375-3380
4. Carlson B., Lahusen T., Singh S., et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59 (1999) 4634-4641
5. Chao S.H., and Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276 (2001) 31793-31799
6. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
7. Fertil B., and Malaise E.P. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 7 (1981) 621-629
8. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
9. Hubeek I., Peters G.J., Broekhuizen A.J., et al. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukemia. Br J Haematol 131 (2005) 219-222
10. Jung C.P., Motwani M.V., and Schwartz G.K. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7 (2001) 2527-2536
11. Kanazawa S., Soucek L., Evan G., Okamoto T., and Peterlin B.M. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 22 (2003) 5707-5711
12. Kaur G., Stetler-Stevenson M., Sebers S., et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84 (1992) 1736-1740
13. Kudo Y., Kitajima S., Ogawa I., Miyauchi M., and Takata T. Down-regulation of cdk inhibitor p27 in oral squamous cell carcinoma. Oral Oncol 41 (2005) 105-116
14. Li Y., Bhuiyan M., Alhasan S., Senderawicz A.M., and Sarkar F.H. Induction of apoptosis and inhibition of c-erb-2 in breast cancer cells by flavopiridol. Clin Cancer Res 6 (2000) 223-229
15. Mason K.A., Hunter N.R., Raju U., et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int J Radiat Oncol Biol Phys 59 (2004) 1181-1189
16. Mason KA, Raju U, Hunter NR, et al. Flavopiridol enhances tumor response to therapy [Abstract]. In: Steven M, Grunberg M, editors. Thiry-ninth annual meeting of the American society of clinical oncology, Chicago, IL 2003;22:865.
17. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6 (1996) 393-397
18. Milas L., Akimoto T., Hunter N.R., et al. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 52 (2002) 514-521
19. Milas L., Raju U., Liao Z., and Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32 (2005) S78-S81
20. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
21. Raju U., Gumin G.J., Noel F., and Tofilon P.J. IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumor cells. Int J Radiat Biol 74 (1998) 617-624
22. Raju U., Nakata E., Mason K.A., Ang K.K., and Milas L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 63 (2003) 3263-3267
23. Rohatgi P.R., Swisher S.G., Correa A.M., et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104 (2005) 1349-1355
24. Sarker A.H., Tsutakawa S.E., Kostek S., et al. Recognition of RNA polymerase II and transcription bubbles by XPG, CSB, and TFIIH: insights for transcription-coupled repair and Cockayne syndrome. Mol Cell 20 (2005) 187-198
25. Schwartz G.K. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23 (2005) 4499-4508
26. Schwartz G.K., and Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23 (2005) 9408-9421
27. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 38 (2001) 139-170
28. Senderowicz A.M. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 52 (2003) S61-S73
29. Senderowicz A.M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16 (2004) 670-678
30. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 (2006) 1770-1783
31. Sutherland R.L., and Musgrove E.A. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4 (2002) 14-17
32. Zhong H., and Bowen J.P. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem 13 (2006) 849-862